bioPROTACs establish RAS as a degradable target and provide novel RAS biology insights

Abstract excerpt

<h4>ABSTRACT</h4> Mutations to RAS proteins (H-, N-, and K-RAS) are amongst the most common oncogenic drivers and tumors harboring these lesions are some of the most difficult to treat. Although the recently discovered covalent small molecules against the KRAS G12C mutant have shown promising efficacy against lung cancers, traditional barriers remain for drugging the more prevalent KRAS G12D and KRAS G12V muta...

Topics

Open a Topic to create a Post that cites this publication.

• Antineoplastic Agents
• Cell Proliferation
• Peptidase Inhibition and Analysis
• Protein Degradation and Inhibitors
• Proteolysis
• Proto-Oncogene Proteins p21(ras)
• Small Molecule Libraries
• Ubiquitin and proteasome pathways

Identifiers and source

Literature Corpus work

39c818a1-cd3f-5ebc-a81e-95660a6cd1fd

DOI

10.1101/2020.06.26.174565